Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles selon la gravité.
RéversibilitéGestionGravité
#3
Comment les complications affectent-elles la qualité de vie ?
Les complications peuvent réduire la qualité de vie en limitant les capacités fonctionnelles.
Qualité de vieCapacités fonctionnellesComplications
#4
Y a-t-il des risques de complications à long terme ?
Oui, des risques de complications à long terme existent, notamment des cancers et des maladies chroniques.
RisquesComplications à long termeMaladies chroniques
#5
Les complications peuvent-elles être prévenues ?
Certaines complications peuvent être prévenues par un suivi médical régulier et des interventions précoces.
PréventionSuivi médicalInterventions
Facteurs de risque
5
#1
Quels sont les facteurs de risque pour les anomalies de polyadénylation ?
Les facteurs incluent des mutations génétiques, des expositions environnementales et des infections.
Facteurs de risqueMutations génétiquesInfections
#2
L'âge est-il un facteur de risque ?
Oui, l'âge avancé peut augmenter le risque de mutations affectant la polyadénylation.
ÂgeMutationsRisque
#3
Les habitudes de vie influencent-elles la polyadénylation ?
Des habitudes comme le tabagisme et l'alcoolisme peuvent affecter les mécanismes de polyadénylation.
Habitudes de vieTabagismeAlcoolisme
#4
Les maladies chroniques augmentent-elles les risques ?
Oui, certaines maladies chroniques peuvent prédisposer à des anomalies de polyadénylation.
Maladies chroniquesPrédispositionAnomalies
#5
Les facteurs génétiques jouent-ils un rôle ?
Oui, des antécédents familiaux de maladies peuvent augmenter le risque d'anomalies de polyadénylation.
Facteurs génétiquesAntécédents familiauxRisque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Signaux de polyadénylation : Questions médicales les plus fréquentes",
"headline": "Signaux de polyadénylation : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Signaux de polyadénylation : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-02",
"dateModified": "2025-03-29",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Signaux de polyadénylation"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Composants de gène",
"url": "https://questionsmedicales.fr/mesh/D040461",
"about": {
"@type": "MedicalCondition",
"name": "Composants de gène",
"code": {
"@type": "MedicalCode",
"code": "D040461",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360.340.024.340.137"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Signaux de polyadénylation",
"alternateName": "RNA 3' Polyadenylation Signals",
"code": {
"@type": "MedicalCode",
"code": "D039104",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Xiaohui Wu",
"url": "https://questionsmedicales.fr/author/Xiaohui%20Wu",
"affiliation": {
"@type": "Organization",
"name": "Department of Automation, Xiamen University, Xiamen, China."
}
},
{
"@type": "Person",
"name": "Guoli Ji",
"url": "https://questionsmedicales.fr/author/Guoli%20Ji",
"affiliation": {
"@type": "Organization",
"name": "Department of Automation, Xiamen University, Xiamen, China."
}
},
{
"@type": "Person",
"name": "Congting Ye",
"url": "https://questionsmedicales.fr/author/Congting%20Ye",
"affiliation": {
"@type": "Organization",
"name": "National Institute for Data Science in Health and Medicine, Xiamen University, Xiamen, China."
}
},
{
"@type": "Person",
"name": "Bin Tian",
"url": "https://questionsmedicales.fr/author/Bin%20Tian",
"affiliation": {
"@type": "Organization",
"name": "Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, PA 19104, USA."
}
},
{
"@type": "Person",
"name": "Mihaela Zavolan",
"url": "https://questionsmedicales.fr/author/Mihaela%20Zavolan",
"affiliation": {
"@type": "Organization",
"name": "Computational and Systems Biology, Biozentrum, University of Basel, Spitalstrasse 41, 4056 Basel, Switzerland."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Validity of the revised Diagnostic and Statistical Manual of Mental Disorders-5 cross-cutting symptom measure as implemented in community mental health settings.",
"datePublished": "2023-10-14",
"url": "https://questionsmedicales.fr/article/37844781",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jad.2023.10.077"
}
},
{
"@type": "ScholarlyArticle",
"name": "Interrater reliability of criterion A of the alternative model for personality disorder (Diagnostic and Statistical Manual for Mental Disorders, Fifth Edition-Section III): A meta-analysis.",
"datePublished": "2023-05-25",
"url": "https://questionsmedicales.fr/article/37227864",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1037/per0000631"
}
},
{
"@type": "ScholarlyArticle",
"name": "Item Response Theory Analyses of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Criteria Adapted to Screen Use Disorder: Exploratory Survey.",
"datePublished": "2022-07-27",
"url": "https://questionsmedicales.fr/article/35896018",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2196/31803"
}
},
{
"@type": "ScholarlyArticle",
"name": "Psychopathy and antisocial personality disorder in the fifth edition of the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders: An attempted replication of Wygant et al. (2016).",
"datePublished": "2023-05-25",
"url": "https://questionsmedicales.fr/article/37227862",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1037/per0000626"
}
},
{
"@type": "ScholarlyArticle",
"name": "Functional impairment, insight, and comparison between criteria for gaming disorder in the International Classification of Diseases, 11 Edition and internet gaming disorder in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.",
"datePublished": "2022-11-02",
"url": "https://questionsmedicales.fr/article/36326855",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1556/2006.2022.00079"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Structures génétiques",
"item": "https://questionsmedicales.fr/mesh/D040342"
},
{
"@type": "ListItem",
"position": 4,
"name": "Génome",
"item": "https://questionsmedicales.fr/mesh/D016678"
},
{
"@type": "ListItem",
"position": 5,
"name": "Composants de génome",
"item": "https://questionsmedicales.fr/mesh/D040481"
},
{
"@type": "ListItem",
"position": 6,
"name": "Gènes",
"item": "https://questionsmedicales.fr/mesh/D005796"
},
{
"@type": "ListItem",
"position": 7,
"name": "Composants de gène",
"item": "https://questionsmedicales.fr/mesh/D040461"
},
{
"@type": "ListItem",
"position": 8,
"name": "Signaux de polyadénylation",
"item": "https://questionsmedicales.fr/mesh/D039104"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Signaux de polyadénylation - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Signaux de polyadénylation",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-11",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Signaux de polyadénylation",
"description": "Comment identifier les signaux de polyadénylation ?\nQuels tests sont utilisés pour étudier la polyadénylation ?\nLes signaux de polyadénylation sont-ils visibles sur des gels ?\nPeut-on détecter des anomalies dans la polyadénylation ?\nQuels marqueurs indiquent une polyadénylation efficace ?",
"url": "https://questionsmedicales.fr/mesh/D039104?mesh_terms=Diagnostic+and+Statistical+Manual+of+Mental+Disorders#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Signaux de polyadénylation",
"description": "Quels symptômes sont liés à des défauts de polyadénylation ?\nLes maladies génétiques sont-elles liées à la polyadénylation ?\nComment la polyadénylation affecte-t-elle le cancer ?\nY a-t-il des symptômes associés à des ARNm instables ?\nLes infections virales affectent-elles la polyadénylation ?",
"url": "https://questionsmedicales.fr/mesh/D039104?mesh_terms=Diagnostic+and+Statistical+Manual+of+Mental+Disorders#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Signaux de polyadénylation",
"description": "Peut-on prévenir les anomalies de polyadénylation ?\nQuel rôle joue l'alimentation dans la polyadénylation ?\nLes facteurs environnementaux affectent-ils la polyadénylation ?\nComment le stress oxydatif influence-t-il la polyadénylation ?\nLes vaccinations influencent-elles la polyadénylation ?",
"url": "https://questionsmedicales.fr/mesh/D039104?mesh_terms=Diagnostic+and+Statistical+Manual+of+Mental+Disorders#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Signaux de polyadénylation",
"description": "Existe-t-il des traitements pour les anomalies de polyadénylation ?\nComment les médicaments peuvent-ils influencer la polyadénylation ?\nLes thérapies ciblées peuvent-elles aider ?\nY a-t-il des approches expérimentales en cours ?\nLes suppléments nutritionnels peuvent-ils aider ?",
"url": "https://questionsmedicales.fr/mesh/D039104?mesh_terms=Diagnostic+and+Statistical+Manual+of+Mental+Disorders#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Signaux de polyadénylation",
"description": "Quelles complications peuvent survenir avec des défauts de polyadénylation ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nY a-t-il des risques de complications à long terme ?\nLes complications peuvent-elles être prévenues ?",
"url": "https://questionsmedicales.fr/mesh/D039104?mesh_terms=Diagnostic+and+Statistical+Manual+of+Mental+Disorders#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Signaux de polyadénylation",
"description": "Quels sont les facteurs de risque pour les anomalies de polyadénylation ?\nL'âge est-il un facteur de risque ?\nLes habitudes de vie influencent-elles la polyadénylation ?\nLes maladies chroniques augmentent-elles les risques ?\nLes facteurs génétiques jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D039104?mesh_terms=Diagnostic+and+Statistical+Manual+of+Mental+Disorders#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les signaux de polyadénylation ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'analyse bioinformatique et les séquençages d'ARN permettent d'identifier ces signaux."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour étudier la polyadénylation ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests RT-PCR et Northern blot sont couramment utilisés pour étudier la polyadénylation."
}
},
{
"@type": "Question",
"name": "Les signaux de polyadénylation sont-ils visibles sur des gels ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les produits de polyadénylation peuvent être visualisés sur des gels d'agarose après électrophorèse."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des anomalies dans la polyadénylation ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies peuvent être détectées par des variations dans la taille des ARNm sur des gels."
}
},
{
"@type": "Question",
"name": "Quels marqueurs indiquent une polyadénylation efficace ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La présence d'une queue poly-A et la stabilité de l'ARNm sont des marqueurs d'efficacité."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à des défauts de polyadénylation ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des défauts peuvent entraîner une instabilité de l'ARNm, affectant la synthèse protéique."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques sont-elles liées à la polyadénylation ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies génétiques peuvent résulter de mutations affectant les signaux de polyadénylation."
}
},
{
"@type": "Question",
"name": "Comment la polyadénylation affecte-t-elle le cancer ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des altérations dans la polyadénylation peuvent conduire à une expression aberrante de gènes oncogènes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes associés à des ARNm instables ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des ARNm instables peuvent entraîner des troubles métaboliques et des anomalies cellulaires."
}
},
{
"@type": "Question",
"name": "Les infections virales affectent-elles la polyadénylation ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales peuvent perturber les signaux de polyadénylation, affectant l'hôte."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies de polyadénylation ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par une bonne santé génétique et des dépistages précoces des maladies."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'alimentation dans la polyadénylation ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut influencer positivement la régulation des gènes liés à la polyadénylation."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux affectent-ils la polyadénylation ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs comme les toxines peuvent perturber les mécanismes de polyadénylation."
}
},
{
"@type": "Question",
"name": "Comment le stress oxydatif influence-t-il la polyadénylation ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress oxydatif peut endommager l'ADN et affecter les signaux de polyadénylation."
}
},
{
"@type": "Question",
"name": "Les vaccinations influencent-elles la polyadénylation ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines recherches suggèrent que les vaccinations peuvent moduler l'expression des gènes liés."
}
},
{
"@type": "Question",
"name": "Existe-t-il des traitements pour les anomalies de polyadénylation ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de traitements spécifiques, mais des thérapies géniques sont explorées."
}
},
{
"@type": "Question",
"name": "Comment les médicaments peuvent-ils influencer la polyadénylation ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments peuvent moduler l'expression des gènes impliqués dans la polyadénylation."
}
},
{
"@type": "Question",
"name": "Les thérapies ciblées peuvent-elles aider ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les thérapies ciblées peuvent potentiellement corriger les défauts de polyadénylation."
}
},
{
"@type": "Question",
"name": "Y a-t-il des approches expérimentales en cours ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sur des inhibiteurs spécifiques de la polyadénylation sont en cours dans des modèles précliniques."
}
},
{
"@type": "Question",
"name": "Les suppléments nutritionnels peuvent-ils aider ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent que des nutriments spécifiques pourraient soutenir la polyadénylation."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des défauts de polyadénylation ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles métaboliques, des cancers et des maladies neurodégénératives."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles selon la gravité."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent réduire la qualité de vie en limitant les capacités fonctionnelles."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de complications à long terme ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des risques de complications à long terme existent, notamment des cancers et des maladies chroniques."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être prévenues ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être prévenues par un suivi médical régulier et des interventions précoces."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les anomalies de polyadénylation ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des mutations génétiques, des expositions environnementales et des infections."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge avancé peut augmenter le risque de mutations affectant la polyadénylation."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles la polyadénylation ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des habitudes comme le tabagisme et l'alcoolisme peuvent affecter les mécanismes de polyadénylation."
}
},
{
"@type": "Question",
"name": "Les maladies chroniques augmentent-elles les risques ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies chroniques peuvent prédisposer à des anomalies de polyadénylation."
}
},
{
"@type": "Question",
"name": "Les facteurs génétiques jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies peuvent augmenter le risque d'anomalies de polyadénylation."
}
}
]
}
]
}
National Institute for Data Science in Health and Medicine, Xiamen University, Xiamen, China.
Key Laboratory of the Ministry of Education for Coastal and Wetland Ecosystems, College of the Environment and Ecology, Xiamen University, Xiamen, China.
Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Graduate Group in Genomics and Computational Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Division of Computational Biomedicine, Department of Biological Chemistry, School of Medicine, University of California, Irvine, CA, United States. Electronic address: wei.li@uci.edu.
The purpose of this study was to validate the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) Cross-Cutting Symptom Measure (CCSM) as a screening tool for a wide variety of disorders w...
Participants (N = 851) were referred for coordinated specialty care services (mean age = 20.26 years (SD = 2.97); 82.5 % Caucasian, 7.5 % African American, 0.7 % Native American, 0.7 % Pacific Islande...
At optimal cut-score, specificity ranged from 57 to 77 % for depression, anxiety, substance use and psychosis domains; sensitivity ranged from 63 to 72 %. Scores for depression, anxiety, substance use...
Criterion measures did not have inter-rater reliabilities as this is generally prohibitive in clinic settings....
The CCSM could provide a first step in screening for multiple disorders; however, it cannot replace structured interviews for making diagnoses related to these conditions....
The alternative model for personality disorder (AMPD) is currently included in Section III of the Diagnostic and Statistical Manual for Mental Disorders, Fifth Edition (DSM-5). This review sought to s...
Screen use is part of daily life worldwide and morbidity related to excess use of screens has been reported. Some use of screens in excess could indicate a screen use disorder (ScUD). An integrative a...
Our goals were (1) to describe screen uses in a general population sample and (2) to test the unidimensionality, local independence, and psychometric properties of the 9 Diagnostic and Statistical Man...
This cross-sectional survey in a French suburban city targeted adults and adolescents. A self-administered questionnaire covered the main types of screens used and their use for various activities in ...
Among the 300 participants, 171 (57.0%) were female (mean age 27 years), 297 (99.0%) used screens, 134 (44.7%) reported at least one criterion (potential problem users), and 5 (1.7%) reported 5 or mor...
We described screen uses in a French community sample and have shown that the adaptation of the DSM-5 IGD to "ScUD" has good psychometric validity and is discriminating, confirming our hypothesis. We ...
This study evaluated the consistency between the International Classification of Diseases, 11th Edition (ICD-11) for gaming disorder (ICD-11-GD) and Diagnostic and Statistical Manual of Mental Disorde...
We recruited 60 participants with GD, 45 participants who engaged in hazardous gaming (HG), and 120 controls based on a diagnostic interview. Their operationalization of functional impairment and stag...
We observed satisfactory consistency (kappa value = 0.80) with a diagnostic accuracy of 91.5% between the ICD-11-GD and DSM-5-IGD criteria. Furthermore, 16 participants with IGD in DSM-5 were determin...
There is a good consistency between ICD-11-GD and DSM-5-IGD criteria. The ICD-11 criteria have a high threshold for diagnosing GD. HG criteria could compensate for this high threshold and identify ind...
The conceptual basis of psychopathology within cancer survivorship is critical, as the chosen conceptualisation informs assessment and explanatory models, as well as interventions and supportive care ...
Age-related psychometric differences in Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) opioid use disorder (OUD) diagnostic criteria have been hypothesized, but not been te...
People who participated in the 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions III and reported past 12-month nonmedical use of prescription opioids were included. YAs were 1...
One in 5 people met the DSM-5 OUD diagnostic criteria for OUD within the past 12 months, with the most endorsed criteria being tolerance (17.96%). DIF was identified for 3 criteria, including (1) taki...
These findings suggest that there may be age-related variations in the DSM-5 OUD diagnostic criteria's ability to detect latent OUD. Future research should identify contributing factors and the influe...
There is a scarcity of summarizing data on the epidemiology of insomnia in older persons, especially when diagnosed with international criteria. This study aimed to estimate the prevalence and correla...
Through PubMed/MEDLINE, EMBASE, and Web of Science (WoS), we searched for relevant articles published before June 28, 2023. The risk of bias was weighed using the Joanna Briggs Institute's (JBI's) cri...
We included 18,270 participants across 16 studies. The male/female ratio was 0.89 (12 studies), and the mean age varied from 65.9 to 83.1 years (8 studies). The pooled prevalence of insomnia was 19.6%...
Nearly one in every five old individuals was considered to have insomnia disorder, which was associated with the gender and the existence of mental health and/or somatic conditions....
We registered the protocol in the International Prospective Register of Systematic Reviews (PROSPERO) with registration number: CRD42022344675....
The alternative model of personality disorders (AMPD) traits were designed to maintain continuity with the Section II personality disorder (PD) diagnoses by retaining the same clinical information. Wh...
The Impact of Event Scale-Revised (IES-R) is a widely used self-report for assessing posttraumatic stress disorder (PTSD), originally aligned with Diagnostic and Statistical Manual of Mental Disorders...
A total of 238 participants recruited from multiple psychiatric centers, including 67 patients with PTSD, 72 patients with psychiatric controls, and 99 healthy controls, were included in the study. Al...
The IES-R demonstrated good internal consistency and a high correlation with the PCL-5. Through factor analysis, 5 distinct dimensions emerged within the IES-R: sleep disturbance, intrusion, hyperarou...
These findings underscore the scale's concurrent validity with the DSM-5 PTSD criteria and its effectiveness as a screening tool. Implementing a cutoff score of 25 on the IES-R can enhance its utility...